Biotest Aktiengesellschaft (BIO3.DE)
EUR 30.2
(0.67%)
EUR 30.2
(0.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 571.3 Million EUR | 24.82% |
| 2022 | 457.7 Million EUR | 16.79% |
| 2021 | 391.9 Million EUR | -1.48% |
| 2020 | 397.8 Million EUR | 14.05% |
| 2019 | 348.8 Million EUR | 30.39% |
| 2018 | 267.5 Million EUR | -30.36% |
| 2017 | 384.1 Million EUR | 40.54% |
| 2016 | 273.3 Million EUR | -6.02% |
| 2015 | 290.8 Million EUR | 90.69% |
| 2014 | 152.5 Million EUR | 462.73% |
| 2013 | 27.1 Million EUR | -50.94% |
| 2012 | 55.23 Million EUR | 166.39% |
| 2011 | -83.19 Million EUR | -348.73% |
| 2010 | -18.54 Million EUR | -175.5% |
| 2009 | -6.73 Million EUR | 16.63% |
| 2008 | -8.07 Million EUR | 9.19% |
| 2007 | -8.88 Million EUR | 0.16% |
| 2006 | -8.9 Million EUR | -17.31% |
| 2005 | -7.58 Million EUR | 61.36% |
| 2004 | -19.64 Million EUR | -62.08% |
| 2003 | -12.11 Million EUR | -50.11% |
| 2002 | -8.07 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 608.5 Million EUR | 6.51% |
| 2024 Q2 | 558 Million EUR | -8.3% |
| 2023 Q4 | 571.3 Million EUR | -9.38% |
| 2023 Q3 | 630.4 Million EUR | 4.41% |
| 2023 Q2 | 603.8 Million EUR | 3.59% |
| 2023 FY | 571.3 Million EUR | 24.82% |
| 2023 Q1 | 582.9 Million EUR | 27.35% |
| 2022 FY | 457.7 Million EUR | 16.79% |
| 2022 Q1 | 418.7 Million EUR | 6.84% |
| 2022 Q2 | 454.8 Million EUR | 8.62% |
| 2022 Q3 | 493 Million EUR | 8.4% |
| 2022 Q4 | 457.7 Million EUR | -7.16% |
| 2021 Q1 | 417.2 Million EUR | 4.88% |
| 2021 Q4 | 391.9 Million EUR | -7.98% |
| 2021 Q2 | 426.6 Million EUR | 2.25% |
| 2021 Q3 | 425.9 Million EUR | -0.16% |
| 2021 FY | 391.9 Million EUR | -1.48% |
| 2020 Q2 | 403.6 Million EUR | 9.73% |
| 2020 FY | 397.8 Million EUR | 14.05% |
| 2020 Q1 | 367.8 Million EUR | 5.45% |
| 2020 Q4 | 397.8 Million EUR | -7.1% |
| 2020 Q3 | 428.2 Million EUR | 6.1% |
| 2019 FY | 348.8 Million EUR | 30.39% |
| 2019 Q3 | 345.2 Million EUR | 13.18% |
| 2019 Q1 | 309.3 Million EUR | 15.63% |
| 2019 Q4 | 348.8 Million EUR | 1.04% |
| 2019 Q2 | 305 Million EUR | -1.39% |
| 2018 FY | 267.5 Million EUR | -30.36% |
| 2018 Q2 | 449.8 Million EUR | 4.95% |
| 2018 Q3 | 233.5 Million EUR | -48.09% |
| 2018 Q1 | 428.6 Million EUR | 11.59% |
| 2018 Q4 | 267.5 Million EUR | 14.56% |
| 2017 Q3 | 381.5 Million EUR | 8.53% |
| 2017 Q4 | 384.1 Million EUR | 0.68% |
| 2017 Q1 | 312.4 Million EUR | 14.31% |
| 2017 Q2 | 351.5 Million EUR | 12.52% |
| 2017 FY | 384.1 Million EUR | 40.54% |
| 2016 FY | 273.3 Million EUR | -6.02% |
| 2016 Q4 | 273.3 Million EUR | 5.28% |
| 2016 Q2 | 235.2 Million EUR | 2.84% |
| 2016 Q3 | 259.6 Million EUR | 10.37% |
| 2016 Q1 | 228.7 Million EUR | -21.35% |
| 2015 FY | 290.8 Million EUR | 90.69% |
| 2015 Q4 | 290.8 Million EUR | 12.32% |
| 2015 Q3 | 258.9 Million EUR | 2.9% |
| 2015 Q2 | 251.6 Million EUR | 14.68% |
| 2015 Q1 | 219.4 Million EUR | 43.87% |
| 2014 Q4 | 152.5 Million EUR | -10.08% |
| 2014 Q3 | 169.6 Million EUR | 8.09% |
| 2014 Q2 | 156.9 Million EUR | 118.22% |
| 2014 Q1 | 71.9 Million EUR | 165.31% |
| 2014 FY | 152.5 Million EUR | 462.73% |
| 2013 Q1 | 100 Thousand EUR | -99.82% |
| 2013 FY | 27.1 Million EUR | -50.94% |
| 2013 Q4 | 27.1 Million EUR | -1.09% |
| 2013 Q3 | 27.4 Million EUR | 416.98% |
| 2013 Q2 | 5.3 Million EUR | 5200.0% |
| 2012 Q4 | 55.23 Million EUR | 199.53% |
| 2012 FY | 55.23 Million EUR | 166.39% |
| 2012 Q1 | -70.1 Million EUR | 15.74% |
| 2012 Q2 | -58.9 Million EUR | 15.98% |
| 2012 Q3 | -55.5 Million EUR | 5.77% |
| 2011 Q4 | -83.19 Million EUR | 30.67% |
| 2011 Q1 | -7.3 Million EUR | 60.63% |
| 2011 Q2 | -6.1 Million EUR | 16.44% |
| 2011 Q3 | -120 Million EUR | -1867.21% |
| 2011 FY | -83.19 Million EUR | -348.73% |
| 2010 Q4 | -18.54 Million EUR | -95.17% |
| 2010 FY | -18.54 Million EUR | -175.5% |
| 2010 Q3 | -9.5 Million EUR | -39.71% |
| 2010 Q2 | -6.8 Million EUR | 44.26% |
| 2010 Q1 | -12.2 Million EUR | -81.28% |
| 2009 FY | -6.73 Million EUR | 16.63% |
| 2009 Q4 | -6.73 Million EUR | 0.0% |
| 2008 FY | -8.07 Million EUR | 9.19% |
| 2007 FY | -8.88 Million EUR | 0.16% |
| 2006 FY | -8.9 Million EUR | -17.31% |
| 2005 FY | -7.58 Million EUR | 61.36% |
| 2004 FY | -19.64 Million EUR | -62.08% |
| 2003 FY | -12.11 Million EUR | -50.11% |
| 2002 FY | -8.07 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 104.992% |
| CureVac N.V. | -360.92 Million EUR | 258.288% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 0.0% |
| BRAIN Biotech AG | -693 Thousand EUR | 82538.672% |
| Formycon AG | 2.45 Million EUR | -23208.854% |
| Heidelberg Pharma AG | -37.6 Million EUR | 1619.11% |
| Medigene AG | -5.72 Million EUR | 10080.783% |